Novo Nordisk Files MAA for Semaglutide to the EMA for Type 2 Diabetes

 Novo Nordisk Files MAA for Semaglutide to the EMA for Type 2 Diabetes

Novo Nordisk Files MAA for Semaglutide to the EMA for Type 2 Diabetes

Shots:

  • The submission is based on 10 PIONEER studies assessing semaglutide vs sitagliptin, empagliflozin, liraglutide and dulaglutide in 9,543 adult patients with type 2 diabetes
  • The collective studies result demonstrated reduction in HbA1c and weight loss with safe & well tolerated data
  • Semaglutide (qd) is an oral GLP-1 receptor agonist administered once-daily with its expected approval in the US, the EU and Canada

Click here to read full press release/ article | Ref: Novo Nordisk | Image: The Local Denmark

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post